Sugi Predict

Sugi Predict / Compounds / SCHEMBL4426593

SCHEMBL4426593

SCHEMBL4426593

CCCCCC[C@@H](C(=O)NO)C(=O)N(C)[C@@H](Cc1ccccc1)C(=O)OC(C)C

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MMP8 P22894 1/20 0.46
▸ BIRC2 Q13490 1/20 0.46
▸ MMP2 P08253 9/20 0.43
▸ MMP3 P08254 8/20 0.43
▸ MMP1 P03956 6/20 0.43
▸ MMP7 P09237 6/20 0.43
▸ MMP9 P14780 1/20 0.41
▸ CTSG P08311 1/20 0.41
▸ CMA1 P23946 1/20 0.41
▸ LTA4H P09960 1/20 0.40
▸ HDAC8 Q9BY41 5/20 0.39
▸ HDAC3 O15379 3/20 0.39
▸ HDAC1 Q13547 2/20 0.39
▸ HDAC2 Q92769 2/20 0.39
▸ HDAC4 P56524 1/20 0.39
▸ HDAC6 Q9UBN7 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4421989 0.84 MMP2 (0.52) MMP8BIRC2MMP2MMP3MMP1
SCHEMBL19945667 0.72 TSHR (0.46) LTA4H
SCHEMBL19945666 0.72 TSHR (0.46) LTA4H
SCHEMBL4420624 0.71 CTSK (0.43) MMP8BIRC2MMP2MMP3MMP1
SCHEMBL4426591 0.71 BIRC2 (0.83) MMP8BIRC2MMP2MMP3MMP1
SCHEMBL10445723 0.70 HDAC8 (0.52) MMP2MMP3MMP1MMP7MMP9
SCHEMBL27725093 0.69 EPHX2 (0.46) BIRC2HDAC1HDAC6
SCHEMBL8509113 0.69 MMP8 (0.53) MMP8MMP2MMP3MMP1MMP7
SCHEMBL27725096 0.69 EPHX2 (0.46) BIRC2HDAC1HDAC6
SCHEMBL10882823 0.69 MMP2 (0.59) MMP8MMP2MMP3MMP1MMP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4238334-B2 — — 2009-03-18 — — JP claimed
US-6790834-B1 Cytostatic agents BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) 2004-09-14 — — US claimed
EP-0925278-B1 CYTOSTATIC HYDROXAMIC ACID DERIVATIVES BRITISH BIOTECH PHARM (GB) 2002-07-17 — — EP claimed
JP-2001500149-A — — 2001-01-09 — — JP claimed
EP-0925278-A1 CYTOSTATIC HYDROXAMIC ACID DERIVATIVES BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1999-06-30 — — EP claimed
WO-1998011063-A1 CYTOSTATIC HYDROXAMIC ACID DERIVATIVES BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1998-03-19 — — WO claimed
US-20220226304-A1 Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase ALKAHEST, INC. 2022-07-21 — — US disclosed
US-11344542-B2 Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase ALKAHEST, INC. (US) 2022-05-31 — — US disclosed
EP-3793602-A1 TREATMENT OF AGING-ASSOCIATED DISEASE WITH MODULATORS OF LEUKOTRIENE A4 HYDROLASE Alkahest, Inc. (US) 2021-03-24 — — EP disclosed
US-20200368220-A1 Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase ALKAHEST, INC. 2020-11-26 — — US disclosed
US-20190350917-A1 Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase ALKAHEST, INC. 2019-11-21 — — US disclosed
US-6790834-B1 Cytostatic agents BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) 2004-09-14 — — US disclosed
US-6462023-B1 SUCH AS 2-HYDROXY-HYDROXYCARBAMOYL-METHYL)-4-METHYL-PENTANOYLAMINE)-2-PHENYL -ETHANOIC ACID CYCLOPENTYL ESTER; INHIBITING HYPERPROLIFERATIVE TUMOURGENIC CELLS SUCH AS MELANOMA AND/OR LYMPHOMA CELLS BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) 2002-10-08 — — US disclosed
US-6169075-B1 ANTITUMOR AGENT INHIBITING THE PROLIFERATION OF A RANGE OF RAPIDLY DIVIDING TUMOUR CELLS LIKE MELANOMA AND/OR LYMPHOMA CELLS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2001-01-02 — — US disclosed
EP-1052986-A1 ANTI-INFLAMMATORY AGENTS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2000-11-22 — — EP disclosed
WO-2000009119-A1 HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF BETA-AMYLOID PRODUCTION BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2000-02-24 — — WO disclosed
WO-1999044602-A1 INFLAMMATORY CELL INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1999-09-10 — — WO disclosed
WO-1999040910-A1 ANTI-INFLAMMATORY AGENTS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1999-08-19 — — WO disclosed
EP-0925278-A1 CYTOSTATIC HYDROXAMIC ACID DERIVATIVES BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1999-06-30 — — EP disclosed
WO-1998011063-A1 CYTOSTATIC HYDROXAMIC ACID DERIVATIVES BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1998-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11344542-B2 Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase LTA4H, LTB4R, LTC4S MMP8 443/4885BIRC2 3960/4885MMP2 507/4885
US-20190350917-A1 Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase LTA4H, LTB4R, LTC4S MMP8 443/4885BIRC2 3960/4885MMP2 507/4885
US-20220226304-A1 Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase LTA4H, LTB4R, LTC4S MMP8 443/4885BIRC2 3960/4885MMP2 507/4885
US-20200368220-A1 Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase LTA4H, LTB4R, LTC4S MMP8 443/4885BIRC2 3960/4885MMP2 507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.